Sinopharm Group Co. Ltd. (FRA:X2S1)
Germany · Delayed Price · Currency is EUR 11.30
+0.10 (0.89%)
Last updated: Jan 30, 2026, 8:14 AM CET
Sinopharm Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 573,564 | 584,508 | 596,570 | 552,148 | 521,051 | 456,415 | |
Revenue Growth (YoY) | -3.29% | -2.02% | 8.04% | 5.97% | 14.16% | 7.32% |
Cost of Revenue | 531,129 | 540,253 | 548,058 | 504,713 | 477,001 | 416,091 |
Gross Profit | 42,434 | 44,255 | 48,512 | 47,434 | 44,051 | 40,323 |
Selling, General & Admin | 24,158 | 25,582 | 26,161 | 24,914 | 23,210 | 21,203 |
Other Operating Expenses | -592.85 | -468.62 | -582.01 | -676.16 | -589.19 | -652 |
Operating Expenses | 25,024 | 26,436 | 26,193 | 24,670 | 23,067 | 21,221 |
Operating Income | 17,410 | 17,819 | 22,318 | 22,764 | 20,984 | 19,102 |
Interest Expense | -2,760 | -2,724 | -2,946 | -3,509 | -3,745 | -3,413 |
Interest & Investment Income | 1,092 | 621.38 | 783.41 | 555.82 | 590.55 | 708.77 |
Earnings From Equity Investments | 1,199 | 1,199 | 1,107 | 1,067 | 1,070 | 987.46 |
Currency Exchange Gain (Loss) | -15.62 | -15.62 | -9.98 | -2.39 | -10.51 | 11.81 |
Other Non Operating Income (Expenses) | -317.76 | -331.44 | -291.8 | -464.32 | -339.47 | -436.02 |
EBT Excluding Unusual Items | 16,608 | 16,568 | 20,962 | 20,411 | 18,549 | 16,961 |
Impairment of Goodwill | -931.2 | -931.2 | -27.02 | -38.98 | -396.06 | -156.29 |
Gain (Loss) on Sale of Investments | -1,656 | -1,650 | -1,986 | -1,892 | -1,094 | -1,320 |
Gain (Loss) on Sale of Assets | 93.77 | 79.91 | 492.31 | 3.11 | 65.87 | 152.96 |
Asset Writedown | -174.8 | -174.76 | -27.88 | -16.81 | -210.8 | -108.81 |
Other Unusual Items | 108.08 | 108.08 | 98.92 | 97.81 | 88.71 | 68.74 |
Pretax Income | 14,047 | 14,001 | 19,512 | 18,564 | 17,003 | 15,598 |
Income Tax Expense | 3,909 | 3,577 | 4,502 | 4,218 | 3,938 | 3,501 |
Earnings From Continuing Operations | 10,139 | 10,424 | 15,010 | 14,345 | 13,065 | 12,097 |
Minority Interest in Earnings | -3,061 | -3,374 | -5,956 | -5,820 | -5,306 | -4,910 |
Net Income | 7,078 | 7,050 | 9,054 | 8,526 | 7,759 | 7,187 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.07 |
Net Income to Common | 7,078 | 7,050 | 9,054 | 8,526 | 7,759 | 7,187 |
Net Income Growth | -14.06% | -22.13% | 6.19% | 9.89% | 7.95% | 14.95% |
Shares Outstanding (Basic) | 3,119 | 3,121 | 3,121 | 3,117 | 3,121 | 3,111 |
Shares Outstanding (Diluted) | 3,119 | 3,121 | 3,121 | 3,117 | 3,121 | 3,111 |
Shares Change (YoY) | -0.36% | - | 0.12% | -0.12% | 0.30% | 4.70% |
EPS (Basic) | 2.27 | 2.26 | 2.90 | 2.74 | 2.49 | 2.31 |
EPS (Diluted) | 2.27 | 2.26 | 2.90 | 2.74 | 2.49 | 2.31 |
EPS Growth | -13.71% | -22.10% | 6.02% | 10.02% | 7.63% | 10.00% |
Free Cash Flow | 18,963 | 10,075 | 15,213 | 18,837 | 7,234 | 9,257 |
Free Cash Flow Per Share | 6.08 | 3.23 | 4.88 | 6.04 | 2.32 | 2.98 |
Dividend Per Share | 0.680 | 0.680 | 0.870 | 0.820 | 0.750 | 0.690 |
Dividend Growth | -21.84% | -21.84% | 6.10% | 9.33% | 8.70% | 15.00% |
Gross Margin | 7.40% | 7.57% | 8.13% | 8.59% | 8.45% | 8.83% |
Operating Margin | 3.03% | 3.05% | 3.74% | 4.12% | 4.03% | 4.18% |
Profit Margin | 1.23% | 1.21% | 1.52% | 1.54% | 1.49% | 1.57% |
Free Cash Flow Margin | 3.31% | 1.72% | 2.55% | 3.41% | 1.39% | 2.03% |
EBITDA | 19,611 | 19,971 | 24,404 | 24,777 | 22,896 | 20,882 |
EBITDA Margin | 3.42% | 3.42% | 4.09% | 4.49% | 4.39% | 4.58% |
D&A For EBITDA | 2,201 | 2,151 | 2,085 | 2,012 | 1,912 | 1,780 |
EBIT | 17,410 | 17,819 | 22,318 | 22,764 | 20,984 | 19,102 |
EBIT Margin | 3.03% | 3.05% | 3.74% | 4.12% | 4.03% | 4.18% |
Effective Tax Rate | 27.83% | 25.55% | 23.07% | 22.72% | 23.16% | 22.44% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.